低中危前列腺癌立体定向放疗应用趋势:美国国家癌症数据库分析
基于美国国家癌症数据库2004至2015年114931例接受根治性放疗的低中危前列腺癌患者,分析立体定向体部放疗(SBRT)相比常规与中度大分割放疗的使用趋势。SBRT比例从2004年0.9%升至2015年19.5%,常规分割从96.3%降至75.8%,中度大分割从2.7%升至4.7%。
要点
- 低中危前列腺癌SBRT使用率从2004年0.9%显著增至2015年19.5%。
- 同期常规分割放疗比例从96.3%降至75.8%,中度大分割从2.7%升至4.7%。
- SBRT患者更多在学术中心治疗、更年轻且收入更高,常用方案为3625 cGy分5次。
核心结论
- 2004至2015年间低中危前列腺癌SBRT使用显著增加,与支持其疗效和良好毒性特征的数据发表相吻合。
研究设计与样本
- 回顾性分析美国国家癌症数据库2004至2015年114931例接受根治性放疗且诊断和治疗信息充足的患者。
- 比较常规分割(180-200 cGy/次且>5次)、中度大分割(>200 cGy/次且>5次)与SBRT(>200 cGy/次且≤5次)的相对使用率,并用逻辑回归估计趋势。
主要发现
- SBRT比例从2004年0.9%增至2015年19.5%。
- 中度大分割从2.7%增至2015年4.7%。
- 常规分割从2004年96.3%降至2015年75.8%。
- 2011年常规分割绝对患者数从2009年14699例 sharp 降至1492例。
- SBRT患者更常见于学术中心、更年轻且收入更高;最常用方案为3625 cGy分5次。
关键数值与推荐
- 常规分割定义为180-200 cGy/次且>5次。
- 中度大分割定义为>200 cGy/次且>5次。
- SBRT定义为>200 cGy/次且≤5次。
- 最常用SBRT方案为3625 cGy分5次。
临床怎么用
- 低中危前列腺癌根治性放疗中SBRT已成为常用选项,2015年占19.5%。
- 学术中心、年轻和高收入患者更可能接受SBRT,提示应用存在机构与人群差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recent studies have demonstrated both safety and efficacy of stereotactic body radiation therapy (SBRT) as monotherapy in the treatment of low and intermediate risk prostate cancer. Our study aims to provide an update analyzing the use of SBRT compared with conventional and hypofractionated regimens in the United States from 2004 to 2015. METHODS: This retrospective review was conducted using the National Cancer Database. We identified 114,931 patients with sufficient diagnostic and treatment information treated with definitive radiation therapy in the United States from 2004 to 2015. The relative utilization of conventional fractionation (defined as 180-200 cGy per fraction and >5 fractions), moderate hypofractionation (defined as >200 cGy per fraction and >5 fractions), and SBRT (defined as >200 cGy per fraction and 5 fractions or less) were compared over the same time period. Logistic regression models were used to estimate trends. Demographic factors were collected and analyzed using chi-squared tests and independent t-tests. RESULTS: The proportion of prostate cancer patients receiving SBRT increased substantially from 0.9% in 2004 to 19.5% in 2015. Moderate hypofractionation exhibited some growth, increasing from 2.7% of patients to 4.7% in 2015. Conventional fractionation use declined significantly from 96.3% in 2004 to 75.8% in 2015. Notably, there was a sharp decline in the absolute number of patients receiving conventional fractionation in 2011, from 14,699 patients treated in 2009 to 1492 in 2011. Patients treated with SBRT were more likely to be treated in academic centers, younger, and have higher income than other fractionation groups. The most frequently used fractionation schedule was 3625 cGy in five fractions. CONCLUSIONS: The use of SBRT for low and intermediate risk prostate cancer has increased significantly from 2004 to 2015, coinciding with recently published data supporting the efficacy and favorable toxicity profile of this technique.
引用
- Malouff TD, Stross WC, Seneviratne DS, et al. Current use of stereotactic body radiation therapy for low and intermediate risk prostate cancer: A National Cancer Database Analysis. Prostate Cancer Prostatic Dis. 2019. PMID: 31780782. doi:10.1038/s41391-019-0191-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。